Obstetrics

Home  >>  Products  >>  Obstetrics

Product Name:Hotgen fFN (Fetal Fibronectin) Test Cassette

Model/Size:20T

CFDA Approval No.:

Methodology:Colloidal gold immunochromatography

Clinical Discipline:Perinatal care

 Hotgen Fetal Fibronectin (fFN) Test Cassette

 

Hotgen fFN CG kit is an accurate and rapid immunochromatografic test for the qualitative determination of Fetal Fibronectin (fFN) in human cervicoviginal secretions as an tool for risk estimation of preterm labor. 

 

fFN: A specific biomarker for risk estimation of preterm delivery 

 

Fetal Fibronectin (fFN) is a protein that acts as a "glue" during pregnancy, attaching amniotic sac to the lining of uterus. Disruption of this interface causes the release of fFN into cervical/vaginal secretions.

As a new-found specific biomarker for preterm delivery, fFN is highly associated with risk of preterm delivery when present in cervicovaginal secretions.  

fFN testing is approved by FDA for use in women from weeks 22 to 35 of pregnancy. 

A positive fFN  test result indicates that a woman have high risk of preterm labor, although it can't tell for sure that she will go into labor soon. A negative result means that preterm delivery will 98% unlikely happen to the pregnant woman within one to two weeks, and the test can be repeated weekly for women who remain at high risk.

 

Benefits of fFN test in summary:

Specific biomarker for risk assessment of preterm labor in women from 22 to 35 weeks of pregnancy

Positive result indicates high risk of preterm delivery

Negative result can almost rule out the possibility of preterm delivery within two weeks

Help avoid unnecessary intervention and  hospitalizations

 

Hotgen Fetal Fibronectin Test Principle

Colloidal gold immunochromatographic method

 

Hotgen Fetal Fibronectin Kit Features

Qualitative fFN measurement

Rapid, accurate, lab quality results within minutes

Ready-to-use reagents

Long shelf life

Easy storage at room temperature

Single dose format: run only the test you need

 

Copyright:Hotgen Biotech Co., Ltd.